Bhutani D - Search Results

1

Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.

Hopson MB, Bhutani D, Sarkaria S, Maurer MS, Griffin JM, Mapara M, Lentzsch S, Chakraborty R. Hopson MB, et al. Among authors: bhutani d. Leuk Lymphoma. 2022 Sep;63(9):2109-2113. doi: 10.1080/10428194.2022.2060502. Epub 2022 Apr 23. Leuk Lymphoma. 2022. PMID: 35465769

2

Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.

Bhutani D, Leng S, Lentzsch S. Bhutani D, et al. Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):555-559. doi: 10.1016/j.clml.2019.03.029. Epub 2019 Apr 1. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31262668 Review.

3

One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Edwards CV, Bhutani D, Mapara M, Radhakrishnan J, Shames S, Maurer MS, Leng S, Wall JS, Solomon A, Eisenberger A, Lentzsch S. Edwards CV, et al. Among authors: bhutani d. Amyloid. 2019;26(sup1):115-116. doi: 10.1080/13506129.2019.1584892. Amyloid. 2019. PMID: 31343323 Clinical Trial. No abstract available.

4

How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Leng S, Bhutani D, Lentzsch S. Leng S, et al. Among authors: bhutani d. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):125-136. doi: 10.1182/hematology.2019000016. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808850 Free PMC article.

5

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Leng S, Bhutani D, Raza S, Assal A, Pan S, Hu J, Wei A, Mapara M, Lentzsch S. Leng S, et al. Among authors: bhutani d. Blood Cancer J. 2020 Feb 3;10(2):13. doi: 10.1038/s41408-020-0278-5. Blood Cancer J. 2020. PMID: 32015343 Free PMC article. Clinical Trial. No abstract available.

6

Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.

Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, Bhutani D, Pregja S, Sanchorawala V, Landau H. Lentzsch S, et al. Among authors: bhutani d. J Clin Oncol. 2020 May 1;38(13):1455-1462. doi: 10.1200/JCO.19.01721. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083996 Free PMC article. Clinical Trial.

7

Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.

Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Bhutani D, et al. Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e155-e157. doi: 10.1016/j.clml.2020.01.016. Epub 2020 Feb 4. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32098724 No abstract available.

8

Diagnosis and management of systemic light chain AL amyloidosis.

Bhutani D, Lentzsch S. Bhutani D, et al. Pharmacol Ther. 2020 Oct;214:107612. doi: 10.1016/j.pharmthera.2020.107612. Epub 2020 Jun 17. Pharmacol Ther. 2020. PMID: 32562825 Review.

9

Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients.

Premkumar V, Bhutani D, Lentzsch S. Premkumar V, et al. Among authors: bhutani d. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):736-743. doi: 10.1016/j.clml.2020.06.023. Epub 2020 Jul 7. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32739311 Review.

10

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.

Li S, Fu J, Yang J, Ma H, Bhutani D, Mapara MY, Marcireau C, Lentzsch S. Li S, et al. Among authors: bhutani d. Blood. 2021 Apr 1;137(13):1754-1764. doi: 10.1182/blood.2020006334. Blood. 2021. PMID: 33036022 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters